Consumer >> Analyst Interviews >> March 27, 2000

Outlook For Drug Chains: Steven Valiquette – Warburg Dillon Read Llc

STEVEN VALIQUETTE, Director, joined UBS Warburg, LLC, in 1997, and is focused primarily on equity research of the specialty pharmaceutical industry. He also covers the pharmacy benefit management industry, and formerly covered the large capitalization pharmaceutical companies, the US wholesale drug distributors and retail pharmacy chains for UBS. Before joining UBS, Mr. Valiquette worked for three years (1995-97) in the equity research department at Schroder & Co., where he was an Associate Analyst in the health care services sector focused on HMOs, nursing home chains, and physician practice management companies. Prior to joining Schroder, he was an associate analyst in the equity research department at Kidder, Peabody (1994), with a focus on consumer staples. Mr. Valiquette graduated from the University of Michigan School of Business Administration with a Bachelor's degree in Finance and Accounting. Profile
TWST: Which companies do you include in your universe of retail drug


Mr. Valiquette: The stocks I cover formally right now are CVS (CVS),

Walgreen (WAG), Rite Aid (RAD) and Longs